Norse: Erdafitinib And Cetrelimab In Urothelial Carcinoma

NORSE: erdafitinib and cetrelimab in urothelial carcinoma

NORSE: erdafitinib + cetrelimab in mUC with FGFR alterations

#ESMO21 Highlights on erdafitinib in adv. urothelial cancer with FGFRa alterations: The NORSE study

European Society for Medical Oncology (ESMO)

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urot...

Promising early results for cetrelimab plus erdafitinib reported for advanced UC | Thomas Powles

Medicine Matters oncology

Erdafitinib +/- cetrelimab in mUC patients with FGFR alterations

The future role of erdafitinib in advanced urothelial carcinoma

BLC2001: erdafitinib for the treatment of metastatic urothelial carcinoma

Key clinical trials in urothelial carcinoma at ESMO 2021

Erdafitinib for bladder cancer: more to come following FDA approval

Evolving landscape of urothelial cancer treatment: erdafitinib or enfortumab vedotin?

An update on erdafitinib for metastatic/uresectable FGFR alteration urothelial carcinoma

Erdafitinib demonstrates efficacy in intermediate-risk NMIBC with FGFR alterations

Dr. Iyer on TRAEs With Erdafitinib in Urothelial Cancer

Phase 3 THOR Study Results: Erdafitinib vs. Chemotherapy in Advanced Urothelial Cancer | CRSF 2024

CRSF - Cancer Research and Statistic Foundation

What role will erdafitinib play in treating metastatic urothelial carcinoma?

THOR: erdafitinib in metastatic urothelial cancer with FGFR alterations

The role of erdafitinib in treating patients with bladder cancer

Erdafitinib: one more tool for bladder cancer

Erdafitinib for FGFR-mutated urothelial carcinoma